Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-02-15
2005-02-15
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C424S199100, C424S231100, C514S04400A, C536S023720, C536S023400, C435S320100, C435S235100, C435S325000, C435S375000, C435S069100, C435S069300
Reexamination Certificate
active
06855317
ABSTRACT:
The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
REFERENCES:
patent: 4859587 (1989-08-01), Roizman
patent: 5632992 (1997-05-01), Nesburn et al.
patent: 5714152 (1998-02-01), Burke et al.
patent: 6200577 (2001-03-01), McLauchlan et al.
patent: 6340577 (2002-01-01), Hope et al.
patent: 6635258 (2003-10-01), Burke et al.
patent: WO 9202251 (1992-02-01), None
patent: WO 9516779 (1995-06-01), None
patent: WO 9705265 (1997-02-01), None
patent: WO 9705265 (1997-02-01), None
Roisman et al. Herpes Simplex Viruses and Their Replication. In: Fundamental Virology, 2nd Edition, ed. Fields et al, Raven Press, New York, p. 849-895.*
NCBI Entrez, locus CAA32299 tegument protein (Human herpesvirus 1) [online] [retrieved Feb. 27, 2004].*
NCBI Entrez, locus CAB06735 tegument protein (Human herpesvirus 2) [online] retrieved Feb. 27, 2003.*
Ettinger et al (Journal of Immunology 60(5):2365-2373, Mar. 1, 1998).*
Bjornberg et al., “dUTPase from Herpes Simplex Virus Type 1; Purification from Infected Green Monkey Kidney (Vero) Cells . . . ” Protein Expresssion and Purification, 1993, 4:149-159.
E. De Plaen et al. (1997) Cloning of Genes Coding for Antigens Recognized by Cytolytic T Lymphocytes,Immunology Methods Manual692-718.
A. Dolan et al. (1998) The Genome Sequence of Herpes Simplex Virus Type 2,Journal of Virology72(3):2010-2021.
G. Elliott and P. O'Hare (1997) Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein,Cell88:223-233.
Koelle et al., “Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells . . . ” Jnl. of Virology, 1998, 72(9): 7476-7483.
D.M. Koelle, (1995) The Roles of T Lymphocytes in Host Responses to Herpes Simplex Virus,Herpes, 2:83-88.
D.M. Koelle et al. (1998) Clearance of HSV-2 from Recurrent Genital Lesions Correlates with Infiltration of HSV-Specific Cytotoxic T Lymphocytes,The Journal of Clinical Investigation101(7):1500-1508.
D.M. Koelle et al. (1997) Preferrential Presentation of Herpes Simplex Virus T-Cell Antigen by HLA DQA1*0501/DQB1*0201 in Comparison to HLA DQA1*0201/DQB1*0201,Human Immunology53(2):195-205.
D.M. Koelle et al. (1994) Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 Lesions,The Journal of Infectious Diseases169:956-61.
D.M. Koelle et al. (1994) Antigenic Specificities of Human CD+T-Cell Clones Recovered from Recurrent Genital Herpes Simples Virus Type 2 Lesions,Journal of Virology68(5):2803-2810.
W.W. Kwok et al. (1999) Peptide Binding Affinity and pH Variation Establish Functional Thresholds for Activation of HLA-DQ-Restricted T Cell Recognition,Human Immunology60(7):619-626.
Paoletti, “Applications of Pox Virus Vectors to Vaccination: An Update,” Proceedings of the National Academy of Science USA, Oct. 1996, 93:11349-11353.
C.M. Posavad et al. (1996) High Frequency of CD8+Cytotoxic T-Lymphocyte Precursors Specific for Herpes Simplex Viruses in Persons with Genital Herpes,Journal of Virology70(11):8165-8168.
S. Reichstetter et al. (1999) MCH-Peptide Ligand Interactions Establish a Functional Threshold for Antigen-Specific T Cell Recognition,Human Immunology60(7):608-618.
B. Roizman et al:, “Herpes Simplex Viruses and Their Replication”, Fundamental Virology, 2ndEdition, ed. Fields et al, Raven Press, New York, pp. 849-895.
Tatman, J.D. et al., “Assembly of Herpes Simplex Virus Type 1 Using a Panel of Recombinant Baculoviruses,”Journal of General Virology, (1994), 75, 1101-1113.
M.A. Tigges et al.(1992) Human CD8+Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones Recognize Diverse Virion Protein Antigens,Journal of Virology, 66(3):1622-1634.
Williams et al., “Characterization of a Herpes Simplex Virus Type 2 Deoxyuridine . . . ” Virology, 1987, 156:282-292.
Williams, “Deoxyuridine Triphosphate Nucleotidohydrolase Induced by Herpes Simplex Virus Type 1,” Jnl. of Biological Chemistry, 1984, 259(16): 10080-10084.
Corey Lawrence
Koelle David M.
Gates & Cooper LLP
Mosher Mary E.
University of Washington
LandOfFree
Immunological herpes simplex virus antigens and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunological herpes simplex virus antigens and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunological herpes simplex virus antigens and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3461887